Brokerages Set Pacira BioSciences, Inc. (NASDAQ:PCRX) Target Price at $22.78

Shares of Pacira BioSciences, Inc. (NASDAQ:PCRX) have been assigned an average rating of “Hold” from the nine research firms that are currently covering the firm, MarketBeat.com reports. One investment analyst has rated the stock with a sell recommendation, five have assigned a hold recommendation and three have given a buy recommendation to the company. The average 1 year target price among analysts that have covered the stock in the last year is $22.78.

PCRX has been the topic of several research analyst reports. Barclays dropped their target price on shares of Pacira BioSciences from $25.00 to $17.00 and set an “equal weight” rating on the stock in a research report on Tuesday, November 12th. Needham & Company LLC upped their target price on Pacira BioSciences from $22.00 to $30.00 and gave the company a “buy” rating in a research report on Monday, January 13th. Truist Financial raised Pacira BioSciences from a “sell” rating to a “hold” rating and lifted their price target for the stock from $8.00 to $25.00 in a research report on Thursday, January 30th. Royal Bank of Canada restated a “sector perform” rating and issued a $18.00 price objective on shares of Pacira BioSciences in a research note on Tuesday, January 14th. Finally, HC Wainwright reiterated a “buy” rating and issued a $39.00 target price on shares of Pacira BioSciences in a research report on Wednesday, December 4th.

Institutional Trading of Pacira BioSciences

A number of hedge funds have recently added to or reduced their stakes in the company. Public Employees Retirement System of Ohio raised its holdings in Pacira BioSciences by 21,458.4% in the 4th quarter. Public Employees Retirement System of Ohio now owns 91,192 shares of the company’s stock worth $1,718,000 after purchasing an additional 90,769 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its stake in Pacira BioSciences by 26.2% in the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 104,855 shares of the company’s stock valued at $1,975,000 after acquiring an additional 21,781 shares during the period. Voloridge Investment Management LLC grew its stake in Pacira BioSciences by 129.2% in the 4th quarter. Voloridge Investment Management LLC now owns 116,149 shares of the company’s stock valued at $2,188,000 after acquiring an additional 65,467 shares during the period. Squarepoint Ops LLC raised its position in Pacira BioSciences by 72.2% during the fourth quarter. Squarepoint Ops LLC now owns 60,836 shares of the company’s stock worth $1,146,000 after acquiring an additional 25,505 shares during the period. Finally, Two Sigma Advisers LP acquired a new stake in shares of Pacira BioSciences in the fourth quarter valued at about $797,000. 99.73% of the stock is owned by hedge funds and other institutional investors.

Pacira BioSciences Trading Down 1.5 %

Pacira BioSciences stock opened at $26.04 on Thursday. The company has a debt-to-equity ratio of 0.51, a quick ratio of 1.89 and a current ratio of 2.25. The stock has a market cap of $1.20 billion, a PE ratio of -12.83 and a beta of 0.80. The stock has a 50-day moving average of $22.38 and a two-hundred day moving average of $18.25. Pacira BioSciences has a one year low of $11.16 and a one year high of $31.67.

Pacira BioSciences Company Profile

Pacira Biosciences, Inc is a holding company, which engages in the provision of non-opioid pain management and regenerative health solutions to improve patients’ journeys along the neural pain pathway. Its products include EXPAREL, iovera, and DepoFoam. The company was founded in December 2006 and is headquartered in Tampa, FL.